Browse > Article
http://dx.doi.org/10.19125/jmrd.2021.5.1.17

Joint Problems in Patients with Mucopolysaccharidosis Type II  

Kim, Min-Sun (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Jiyeon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Noh, Eu Seon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Chiwoo (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Cho, Sung Yoon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Jin, Dong-Kyu (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Journal of mucopolysaccharidosis and rare diseases / v.5, no.1, 2021 , pp. 17-21 More about this Journal
Abstract
Hunter syndrome or mucopolysaccharidosis type II (MPS-II) (OMIM 309900) is a rare lysosomal storage disorder caused by deficiency in the activity of the enzyme iduronate-2-sulfatase. This enzyme is responsible for the catabolism of the following two different glycosaminoglycans (GAGs): dermatan sulfate and heparan sulfate. The lysosomal accumulation of these GAG molecules results in cell, tissue, and organ dysfunction. Patients can be broadly classified as having one of the following two forms of MPS II: a severe form and an attenuated form. In the severe form of the disease, signs and symptoms (including neurological impairment) develop in early childhood, whereas in the attenuated form, signs and symptoms develop in adolescence or early adulthood, and patients do not experience significant cognitive impairment. The involvement of the skeletal-muscle system is because of essential accumulated GAGs in joints and connective tissue. MPS II has many clinical features and includes two recognized clinical entities (mild and severe) that represent two ends of a wide spectrum of clinical severities. However, enzyme replacement therapy is likely to have only a limited impact on bone and joint disease based on the results of MPS II studies. The aim of this study was to review the involvement of joints in MPS II.
Keywords
Hunter syndrome; Lysosomal storage disease; Mucolopysaccharidosis type II; Joint;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Froissart R, Moreira da Silva I, Guffon N, Bozon D, Maire I. Mucopolysaccharidosis type II--genotype/phenotype aspects. Acta Paediatr Suppl 2002;91:82-7.
2 Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 2004;144:S27-34.   DOI
3 Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 2005;32:270-2.   DOI
4 Schmitt HP. Changes in the voluntary muscles and the peripheral nerves in an autopsy case of MPS type II (Hunter). Neuropediatrics 1981;12:83-91.   DOI
5 Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983;25:481-9.   DOI
6 Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8.   DOI
7 Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007;90:171-80.   DOI
8 Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw Hill, 1995:2465-94.
9 Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw Hill, 2001.
10 Mossman J, Blunt S, Stephens R, Jones EE, Pembrey M. Hunter's disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene. Arch Dis Child 1983;58:911-5.   DOI
11 Van Meir N, De Smet L. Carpal tunnel syndrome in children. Acta Orthop Belg 2003;69:387-95.
12 Morini SR, Steiner CE, Gerson LB. Mucopolysaccharidosis type II: skeletal-muscle system involvement. J Pediatr Orthop B 2010;19:313-7.   DOI
13 Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167:267-77.   DOI
14 Marucha J, Jurecka A, Syczewska M, Rozdzynska-Swiatkowska A, Tylki-Szymanska A. Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status. Acta Paediatr 2012;101:e183-8.   DOI
15 Norman-Taylor F, Fixsen JA, Sharrard WJ. Hunter's syndrome as a cause of childhood carpal tunnel syndrome: a report of three cases. J Pediatr Orthop B 1995;4:106-9.   DOI
16 Wraith JE, Alani SM. Carpal tunnel syndrome in the mucopolysaccharidoses and related disorders. Arch Dis Child 1990;65:962-3.   DOI
17 McArthur RG, Hayles AB, Gomez MR, Bianco AJ, Jr. Carpal tunnel syndrome and trigger finger in childhood. Am J Dis Child 1969;117:463-9.
18 Oniankitan O, Kakpovi K, Fianyo E, Tagbor KC, Houzou P, Koffi-Tessio V, et al. [Risk factors of hip osteoarthritis in Lome, Togo]. Med Trop (Mars) 2009;69:59-60.
19 Bona I, Vial C, Brunet P, Couturier JC, Girard-Madoux M, Bady B, et al. Carpal tunnel syndrome in Mucopolysaccharidoses. A report of four cases in child. Electromyogr Clin Neurophysiol 1994;34:471-5.
20 Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, et al. Multidisciplinary management of Hunter syndrome. Pediatrics 2009;124:e1228-39.   DOI
21 Link B, de Camargo Pinto LL, Giugliani R, Wraith JE, Guffon N, Eich E, et al. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop Rev (Pavia) 2010;2:e16.
22 Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.   DOI
23 Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2009;32:534-43.   DOI
24 Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-73.   DOI
25 Crawley AC, Niedzielski KH, Isaac EL, Davey RC, Byers S, Hopwood JJ. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 1997;99:651-62.   DOI
26 Dorfman A, Matalon R. The mucopolysaccharidoses (a review). Proc Natl Acad Sci U S A 1976;73:630-7.   DOI
27 Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008;121:e377-86.   DOI
28 Norrdin RW, Simske SJ, Gaarde S, Schwardt JD, Thrall MA. Bone changes in mucopolysaccharidosis VI in cats and the effects of bone marrow transplantation: mechanical testing of long bones. Bone 1995;17:485-9.   DOI
29 Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 2000;156:925-38.   DOI
30 Pastores GM, Meere PA. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol 2005;17:70-8.   DOI
31 Miner ME, Schimke RN. Carpal tunnel syndrome in pediatric mucopolysaccharidoses. Report of four cases. J Neurosurg 1975;43:102-3.   DOI
32 Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001;81:1319-28.   DOI
33 Simonaro CM, D'Angelo M, He X, Eliyahu E, Shtraizent N, Haskins ME, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008;172:112-22.   DOI
34 Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005;57:701-7.   DOI
35 Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 2010;107:222-7.   DOI
36 MPS II-SGM-HCPA, Servic,o de Gene' tica Me' dica - Hospital de Clinicas de Porto Alegre RS, Brasil. Mucopolissacaridose II 2004:6.